Episode Details
Back to Episodes
Episode 67: The Analysis of Direct and Indirect Pathways in Observational Studies
Description
In this episode, Jullia and Tom discuss direct and indirect pathways in observational studies, with a focus on mediation analysis and what it can, and cannot, show. Using an ankylosing spondylitis example, they look at how fatigue, anxiety/depression, and work productivity loss can be mapped as exposure, mediator, and outcome, and why interpretation needs care when the data are observational.
Key Takeaways
- Direct and indirect pathways in this context refer to mediation analysis, not basal ganglia movement-control circuits.
- Mediation analysis can help examine whether an observed relationship may operate through an intermediate variable, but it does not prove causality on its own.
- The practical value of pathway analysis depends on clear hypotheses, suitable variable measurement, uncertainty assessment, and careful interpretation.
🔗 Learn More & Get Support: Visit quanticate.com to explore our biometrics services and discover how we can support your next clinical trial.
📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast.
🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode.
About Quanticate
Founded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in:
- Clinical Data Capture & Management
- Biostatistics & Statistical Consultancy
- Statistical Programming & PK/PD Analysis
- Medical Writing & Pharmacovigilance
- Regulatory & Submission Support
- AI & Automation
- Post-Marketing Safety & Real-World Data
Quanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.